Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib

Carfilzomib, a second-generation proteasome inhibitor, has significantly improved the survival rate of multiple myeloma (MM) patients, but its clinical application is still restricted by drug resistance and cardiotoxicity. Here, we identified a novel proteasome inhibitor, D395, and assessed its effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xuxing, Wu, Chao, Lei, Meng, Yan, Qing, Zhang, Haoyang, Zhang, Lina, Wang, Xueyuan, Yang, Ye, Li, Jianyong, Zhu, Yongqiang, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087809/
https://www.ncbi.nlm.nih.gov/pubmed/33931582
http://dx.doi.org/10.1038/s41419-021-03701-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087809/
https://www.ncbi.nlm.nih.gov/pubmed/33931582
http://dx.doi.org/10.1038/s41419-021-03701-z

Ejemplares similares